The objective of the current study was therefore to: (a) calibrate the transition probabilities of a Markov model of adjuvant trastuzumab versus standard chemotherapy in HER2-positive, early breast cancer and (b) compare the survival outcomes on pre-calibrated and calibrated transition probabilities. This evidence concerns the gene ERBB2 and breast cancer.